ZURA

Zura Bio Ltd Health Care Biological Products, (No Diagnostic Substances) Russell 3000

$4.04Close $297.7MMarket cap $3.36 – $7.0452-week range Late-januaryNext report · estimated

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Oct 27, 2026

Off 12-month high 43%

1wk 20.2% price change

1mo 2.9% price change

12-month return 8% market up 11% · its own down 4%

F-score — — Not assessed

Altman Z — Unknown

P/E — price / earnings

PEG — P/E / EPS growth

P/B 2.9× price / book

Earnings yield 40.0% EBIT / enterprise value

Cheaper than — of the market · not assessed

Revenue growth — year on year

EPS growth — latest quarter

Sales growth — latest quarter

ROE 55% return on equity

Free cash margin — -$64.9M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Shareholders diluted The share count rose 12.8% over the year, from 65m to 74m shares. Each existing share owns a smaller fraction of the company than it did a year ago.

Last reported Oct 27, 2026

Last shock Oct 22, 2026-15% in one session3.2× volumeno filing matched+14% since

Financials

4 fiscal years · from filings

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$68.7M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$64.9M

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 73.68m +26240.9% since FY2022

	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Operating income	-$27.2M	-$62.6M	-$55.2M	-$75.2M
Net income	-$25.7M	-$60.4M	-$52.4M	-$68.7M
Earnings per share	-$112.65	-$1.83	-$0.70	-$0.73
Free cash flow	-$1.2M	-$15.1M	-$28.2M	-$64.9M
Cash	$13,785	$99.8M	$176.5M	$109.4M
Shareholders' equity	-$32.1M	$59.3M	$146.8M	$101.5M
Shares outstanding	279.72k	43.59m	65.30m	73.68m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Oct 27, 2026	Quarterly ↗	Sep 30, 2026	27d
Aug 11, 2026	Quarterly ↗	Jun 30, 2026	42d
May 7, 2026	Quarterly ↗	Mar 31, 2026	37d
Mar 19, 2026	Annual ↗	Dec 31, 2025	78d
Nov 13, 2025	Quarterly ↗	Sep 30, 2025	44d
Aug 14, 2025	Quarterly ↗	Jun 30, 2025	45d
May 8, 2025	Quarterly ↗	Mar 31, 2025	38d
Mar 25, 2025	Annual ↗	Dec 31, 2024	84d
Nov 7, 2024	Quarterly ↗	Sep 30, 2024	38d
Aug 13, 2024	Quarterly ↗	Jun 30, 2024	44d
May 9, 2024	Quarterly ↗	Mar 31, 2024	39d
Mar 28, 2024	Annual ↗	Dec 31, 2023	88d

Current reports

Filed	Disclosed
Oct 27, 2026	Results · Regulation FD ↗
Aug 17, 2026	Regulation FD ↗
Aug 11, 2026	Results · Regulation FD ↗
Jul 1, 2026	Regulation FD ↗
Jun 18, 2026	Director or officer change · Shareholder vote ↗
May 22, 2026	Director or officer change ↗
May 7, 2026	Results · Regulation FD ↗
Apr 23, 2026	Director or officer change ↗
Mar 19, 2026	Results · Regulation FD ↗
Mar 10, 2026	Regulation FD ↗
Mar 5, 2026	Regulation FD ↗
Feb 26, 2026	Material agreement · Results · Other events ↗